Myelofibrosis is an intramedullary reactive phenomenon, characteristic of the life-threatening myeloproliferative neoplasm of primary myelofibrosis (PMF). 1 Clinically indistinguishable from PMF are the advanced phases of both polycythemia vera (PV) and essential thrombocythemia (ET), in which myelofibrosis is also present (post-PV and post-ET myelofibrosis, respectively (post-PV/ ET MF)). 1 Patients with PMF (or post-ET/PV MF) have a progressive decline marked by progressive cytopenias, extramedullary hematopoiesis (manifesting as splenomegaly and/or hepatomegaly), significant constitutional symptoms, potential for blastic transformation and premature death. 2 Medical therapy for these patients has been disappointing, with clinical benefit being best categorized as palliative with only cosmetic improvements in anemia, splenomegaly or constitutional symptoms seen. 2 Allogeneic stem cell transplantation can be utilized; however, a minority of patients remain appropriate candidates because of non-relapse morbidity and mortality, advanced age at diagnosis, comorbidities or lack of a suitable donor. 2 The urgent need for improved therapeutic options for myelofibrosis patients has fueled scientific investigation into the pathogenetic origins of the disorder in the hope of increasing efficacy through targeted therapy. PMF has been demonstrated to be a stem cell disorder, leading to a clonal myeloproliferation. 3 Origins of the clonal drive are incompletely understood, but are likely, at least in part, secondary to the recently described mutations in the activation of the JAK-STAT pathway by either the JAK2 V617F and/or the MPL W515L/K mutations, which lead to downstream activation of cellular proliferation. 3 In aggregate, these mutations are present in about 50-65% of patients with PMF and post-ET MF, and the majority (V617F only) in post-PV MF. Therapeutic targeting of these latter mutations are currently undergoing initial clinical testing with intriguing results. 4 Prior to the targeting of myeloproliferative neoplasm-associated mutations in cell signaling, therapeutic efforts for myelofibrosis focused on targeting the reactive myelofibrosis in the hope of therapeutic gain.
The significant polyclonal stromal reaction present in PMF (and post-ET/PV MF) leads not only to significant deposition of reticulin fibrosis, but also to collagen fibrosis, osteosclerosis and neoangiogenesis. Increases in several key cytokines have been demonstrated in these patients including transforming growth factor-b1, platelet-derived growth factor and tumor necrosis factor-a. 3 Several clinical trials have been utilized with agents targeting one or more of these aberrant cytokines, in the hope of altering the phenotype of myelofibrosis to that of a less morbid myeloproliferative neoplasm such as PV or ET. Utilizing this strategy, immunomodulatory agents that target tumor necrosis factor-a (with either thalidomide or lenalidomide) 5 have shown clinical benefit. Bortezomib (VELCADE; Millenium Pharmaceuticals Inc. and Johnson & Johnson Pharmaceutical Research and Development, LLC, Cambridge, MA, USA) is a proteosome inhibitor with the ability to inhibit nuclear factor-kB, making it of interest in myelofibrosis. In addition, bortezomib has been shown to (1) inhibit thrombopoietin-induced nuclear factor-kB activation in murine megakaryocytes (2) in murine model of myelofibrosis, therapy with bortezomib decreased transforming growth factor-b1, decreased osteosclerosis, inhibited the cytokine osteoprotegerin and led to increased survival. 6 On the basis of the murine data, theoretical activity by cytokine inhibition, preliminary activity demonstrated in the related myeloid disorder of myelodysplastic syndrome 7 and tolerability shown in the Food and Drug Administration (FDA)-indicated use of bortezomib in myeloma, a multicenter pilot phase II clinical trial for patients with symptomatic PMF (and post-ET/PV MF) was initiated.
A total of 11 patients were enrolled in the trial, nine with myelofibrosis (seven with PMF (78%), two with post-ET MF (22%); post-PV MF patients were eligible, however, none were enrolled), and one patient each with either refractory systemic mast cell disease or chronic myelomonocytic leukemia. Symptomatic and therapy-requiring patients (characteristics and demographic information listed in Table 1 ) began therapy with bortezomib at the dosing schedule utilized in myelodysplastic syndrome (1.6 mg m
À2
intravenously weekly Â 4 weeks; cycles every 5 weeks 7 ). Among those patients without either response or significant toxicity (pgrade 3), the dose would be increased to the standard dose utilized in the FDA indication of myeloma, namely 1.3 mg m À2 intravenously twice weekly Â 2 weeks; cycles every 3 weeks. A median of two cycles was given per patient (range 1-4), and 4 out of 11 patients (36%) underwent the dose escalation allowed by protocol for lack of efficacy (3/9 myelofibrosis patients (33%)). Seven out of the nine (78%) myelofibrosis patients experienced a grade 3 toxicity at least possibly related to bortezomib, of which five were non-hematologic (71%). Among these latter events, one patient developed a significant non-infectious pneumonitis possibly related to bortezomib use (full details of toxicities are listed in Table 2 ).
Therapy with bortezomib was clinically ineffective for the patients with myelofibrosis. Utilizing the International Working Group for Myelofibrosis Research and Treatment response criteria, no patient achieved even a clinical improvement (CI: the minimal response recognized) in eligible categories (neutropenia or thrombocytopenia was not present at baseline based on entry criteria) including splenomegaly or anemia (see Table 2 ). The patient with chronic myelomonocytic leukemia did not have clinical benefit from the bortezomib and had worsening monocytosis and skin lesions, was taken off study after three cycles and subsequently responded to decitabine. The patient with systemic mast cell disease also had no clinical demonstration of response. Due to the lack of efficacy among the patients enrolled, the trial was halted.
The lack of clinical benefit seen with bortezomib therapy in myelofibrosis was disappointing, given the pre-clinical demonstration of myelofibrosis inhibition in the murine model. 6 Our results recapitulate the lack of clinical efficacy described in the preliminary report of a phase I trial of bortezomib in myelofibrosis, where at a maximal tolerated level of 1.3 mg m À2 for 4 days every 3 weeks, no responses (by International Working Group for Myelofibrosis Research and Treatment criteria) were documented. 8 Lack of clinical efficacy of bortezomib in myelofibrosis may underscore further that preclinical analysis of therapeutic agents that inhibit alternate forms of secondary myelofibrosis (such as thrombopoietin-driven murine models 6 ) may not accurately predict clinical activity in PMF and post-ET/PV MF patients. Indeed, the central myeloproliferative drive in these individuals, which is at least in part tyrosine kinase-driven (JAK2 V617F , JAK2 Exon 12 mutations, or MPL mutations), 3 may well require blockade of these central stimulatory pathways to truly impact the disease. Murine models have been described driven by these mutations, yielding both a myeloproliferative neoplasm and a myelofibrosis phenotype. 3 Clinical trials have now been initiated with selective inhibitors of JAK2 using agents such as INCB018424, XL019 and TG101348, all of which have demonstrated activity in these models. 4 Results are awaited with great expectation to assess the validity of JAK2 inhibition as a therapeutic target, and the predictive value of therapeutic efficacy in the JAK2 mutant murine models. Non-hematologic Grades 1-2 n ¼ 6 events; sensory
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Response ( Detection of minimal residual disease (MRD) has become a strong diagnostic tool in acute leukemia. In acute lymphoblastic leukemia, it is widely used for risk-adapted therapy. In acute myeloid leukemia (AML), it is still a matter of debate how best to measure MRD. A number of different methods are competing. 1, 2 In the comparison of these methods, it has become common practice to advertise the high sensitivity of one or the other method. In this context, sensitivity usually means the lowest proportion of leukemic cells that can be measured. Unfortunately, this type of sensitivity is not only a technically incorrect use of the word, but also information with very limited relevance. The crucial point is not the lowest proportion of leukemic cells that is measurable, but the lowest proportion of leukemic cells that are clearly distinguishable from any healthy or, even more importantly, any leukemia-free, regenerating bone marrow. Here we discuss the importance of these differences and the consequences for comparing different methods of detecting MRD.
The sensitivity of a diagnostic test is defined as the likelihood of a positive test result in a truly positive patient. This definition is only applicable to tests with dichotomous results. Measurement of MRD gives continuous results, but cutoffs are defined for clinical decision-making. Therefore, patients are classified in a dichotomous manner as high-MRD (above the threshold) or low-MRD (below the threshold).
In this setting, different methods of monitoring MRD can be compared using the terms sensitivity and specificity. The sensitivity is the likelihood of classifying patients as high MRD if the percentage of leukemic cells in their bone marrow is really higher than the threshold. The specificity of the method is the likelihood of classifying patients as low MRD if the percentage of leukemic cells in their bone marrow is really lower than the threshold.
Both sensitivity and specificity strongly depend on the threshold that is used. For different clinical questions, different thresholds could be relevant. Therefore, it is meaningless to talk about the sensitivity or the specificity of monitoring MRD without defining the threshold that one is interested in.
Another important issue is that sensitivity and specificity of detecting MRD vary from patient to patient. They depend on the copy numbers of the leukemia-associated genes (WT1, PRAME and others [3] [4] [5] ) that are used for PCR or the quality of the leukemiaassociated phenotypes that are used for flow cytometry. 6 Therefore, any statement on the quality of a method of monitoring MRD should include the following data: the threshold that is used for clinical decision-making, sensitivity, specificity and the proportion of patients for whom this level of quality can be achieved. For instance, the statement could be: At a threshold of 1 leukemic cell in 1000 healthy bone marrow cells, this method allows one to measure MRD with a sensitivity X80% and a specificity X90 in 70% of all AML patients.
Throughout the literature on MRD, it is difficult to find any paper that includes this complete set of information. The main problem is that we do not have a gold standard for the monitoring of MRD.
In papers about MRD, the term sensitivity is often used in a completely different way. It is used to describe the lowest proportion of leukemic cells that gives a positive test result.
A commonly performed experiment to determine this type of sensitivity is to establish serial dilution of leukemic cells in a sample of healthy bone marrow. The healthy bone marrow that is selected for this experiment is usually completely negative for the MRD marker. The lowest proportion of leukemic cells, which still gives a positive test result, is then called the sensitivity of the test.
A better term for this type of sensitivity would be lowest possible threshold (LPT) because it is not the sensitivity of the diagnostic test (likelihood of a positive test result in a truly positive patient).
These experiments provide useful information only if the test is 100% specific for leukemic cells, that is, if every healthy bone marrow gives completely negative result.
Real-time PCR for immunoglobulin rearrangements (acute lymphoblastic leukemia) 7 or specific mutations (AML) 1,2 are highly specific methods of measuring MRD. Flow cytometry or real-time PCR for leukemia-associated genes (WT1, PRAME and others) always give a certain amount of positivity in leukemiafree samples (Lapillone et al. The first step to answer this question is to apply the method to samples of bone marrow from a large number of healthy
